Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults
PHASE1CompletedINTERVENTIONAL
Enrollment
44
Participants
Timeline
Start Date
August 31, 2004
Study Completion Date
August 31, 2005
Conditions
RECOMBINANT BOTULINUM VACCINE A/B
Interventions
BIOLOGICAL
rBV A/B
Trial Locations (1)
40536
University of Kentucky Medical Center, Lexington
All Listed Sponsors
lead
DynPort Vaccine Company LLC, A GDIT Company
INDUSTRY
NCT00098098 - Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults | Biotech Hunter | Biotech Hunter